Y. Aalto, L. Eriksson, S. Seregard, O. Larsson, and S. Knuutila, Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma, Invest Ophthalmol Vis Sci, vol.42, pp.313-317, 2001.

J. Ackermann, M. Frutschi, K. Kaloulis, T. Mckee, A. Trumpp et al., Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background, Cancer Res, vol.65, pp.4005-4011, 2005.

I. Adameyko, F. Lallemend, J. B. Aquino, J. A. Pereira, P. Topilko et al., Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin, Cell, vol.139, pp.366-379, 2009.

A. P. Algazi, K. K. Tsai, A. N. Shoushtari, R. R. Munhoz, Z. Eroglu et al., Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies, Cancer, vol.122, pp.3344-3353, 2016.

M. Allegra, D. Giacchero, C. Segalen, N. Dumaz, C. Butori et al., A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib, J Invest Dermatol, vol.134, pp.1473-1476, 2014.
URL : https://hal.archives-ouvertes.fr/inserm-02530592

S. Alsafadi, A. Houy, A. Battistella, T. Popova, M. Wassef et al., Cancerassociated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage, Nature communications, vol.7, p.10615, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01272099

H. K. An, K. S. Kim, J. W. Lee, M. H. Park, H. I. Moon et al., Mimulone-induced autophagy through p53-mediated AMPK/mTOR pathway increases caspase-mediated apoptotic cell death in A549 human lung cancer cells, PloS one, vol.9, p.114607, 2014.

H. Aoki, Y. Yamada, A. Hara, and T. Kunisada, Two distinct types of mouse melanocyte: differential signaling requirement for the maintenance of noncutaneous and dermal versus epidermal melanocytes, Development, vol.136, pp.2511-2521, 2009.

L. G. Aoude, K. A. Wadt, A. L. Pritchard, and N. K. Hayward, Genetics of familial melanoma: 20 years after CDKN2A, Pigment Cell Melanoma Res, vol.28, pp.148-160, 2015.

R. Arafeh, N. Qutob, R. Emmanuel, K. , A. Madore et al., Recurrent inactivating RASA2 mutations in melanoma, Nat Genet, vol.47, pp.1408-1410, 2015.

J. H. Arrington, R. J. Reed, H. Ichinose, and E. T. Krementz, Plantar lentiginous melanoma: a distinctive variant of human cutaneous malignant melanoma, The American journal of surgical pathology, vol.1, pp.131-143, 1977.

S. Bakalian, J. C. Marshall, P. Logan, D. Faingold, S. Maloney et al., Molecular pathways mediating liver metastasis in patients with uveal melanoma, Clin Cancer Res, vol.14, pp.951-956, 2008.

C. M. Balch, A. C. Buzaid, S. J. Soong, M. B. Atkins, N. Cascinelli et al., New TNM melanoma staging system: linking biology and natural history to clinical outcomes, vol.21, pp.43-52, 2003.

M. L. Barrenas and F. Lindgren, The influence of inner ear melanin on susceptibility to TTS in humans, Scandinavian audiology, vol.19, pp.97-102, 1990.

B. C. Bastian, The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia, Annual review of pathology, vol.9, pp.239-271, 2014.

B. C. Bastian, P. E. Leboit, H. Hamm, E. B. Brocker, and D. Pinkel, Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization, Cancer Res, vol.58, pp.2170-2175, 1998.

J. Bauer, J. A. Curtin, D. Pinkel, and B. C. Bastian, Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations, J Invest Dermatol, vol.127, pp.179-182, 2007.

C. Beadling, E. Jacobson-dunlop, F. S. Hodi, C. Le, A. Warrick et al., KIT gene mutations and copy number in melanoma subtypes, Clin Cancer Res, vol.14, pp.6821-6828, 2008.

T. C. Beller, A. Maekawa, D. S. Friend, K. F. Austen, and Y. Kanaoka, Targeted gene disruption reveals the role of the cysteinyl leukotriene 2 receptor in increased vascular permeability and in bleomycin-induced pulmonary fibrosis in mice, J Biol Chem, vol.279, pp.46129-46134, 2004.

D. C. Bennett, How to make a melanoma: what do we know of the primary clonal events?, Pigment Cell Melanoma Res, vol.21, pp.27-38, 2008.

M. F. Berger, E. Hodis, T. P. Heffernan, Y. L. Deribe, M. S. Lawrence et al., Melanoma genome sequencing reveals frequent PREX2 mutations, Nature, vol.485, pp.502-506, 2012.

C. Bertolotto, Melanoma: from melanocyte to genetic alterations and clinical options, p.635203, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02530599

C. Bertolotto, A. P. Hemesath, T. J. Bille, K. Fisher, D. E. Ortonne et al., Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes, J Cell Biol, vol.142, pp.827-835, 1998.
URL : https://hal.archives-ouvertes.fr/inserm-02532974

C. Bertolotto, R. Busca, A. P. Bille, K. Aberdam, E. Ortonne et al., Different cis-acting elements are involved in the regulation of TRP1 and TRP2 promoter activities by cyclic AMP: pivotal role of M boxes (GTCATGTGCT) and of microphthalmia, Mol Cell Biol, vol.18, pp.694-702, 1998.
URL : https://hal.archives-ouvertes.fr/inserm-02533084

C. Bertolotto, F. Lesueur, S. Giuliano, T. Strub, M. De-lichy et al., A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma, Nature, vol.480, pp.94-98, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00719536

A. Besaratinia and G. P. Pfeifer, Sunlight ultraviolet irradiation and BRAF V600 mutagenesis in human melanoma, Hum Mutat, vol.29, pp.983-991, 2008.

A. Besaratinia, T. W. Synold, B. Xi, and G. P. Pfeifer, G-to-T transversions and small tandem base deletions are the hallmark of mutations induced by ultraviolet a radiation in mammalian cells, Biochemistry, vol.43, pp.8169-8177, 2004.

M. Bhat, N. Robichaud, L. Hulea, N. Sonenberg, J. Pelletier et al., Targeting the translation machinery in cancer, Nature reviews Drug discovery, vol.14, pp.261-278, 2015.

A. Blangy, N. Bouquier, C. Gauthier-rouviere, S. Schmidt, A. Debant et al., Identification of TRIO-GEFD1 chemical inhibitors using the yeast exchange assay, Biology of the cell, vol.98, pp.511-522, 2006.
URL : https://hal.archives-ouvertes.fr/hal-02267406

C. Bonet, F. Luciani, J. F. Ottavi, J. Leclerc, F. M. Jouenne et al., Deciphering the role of oncogenic MITFE318K in senescence delay and melanoma progression J Natl Cancer, 2017.

L. Boussemart, H. Malka-mahieu, I. Girault, D. Allard, O. Hemmingsson et al., eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies, Nature, vol.513, pp.105-109, 2014.

M. A. Brantley and J. W. Harbour, Deregulation of the Rb and p53 pathways in uveal melanoma, Am J Pathol, vol.157, pp.1795-1801, 2000.

, Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region, Cancer Res, vol.60, pp.4320-4323, 2000.

M. Brenner and V. J. Hearing, The protective role of melanin against UV damage in human skin, Photochemistry and photobiology, vol.84, pp.539-549, 2008.

B. Bressac-de-paillerets, M. F. Avril, A. Chompret, and F. Demenais, Genetic and environmental factors in cutaneous malignant melanoma, Biochimie, vol.84, pp.67-74, 2002.

M. Bronner-fraser, Neural crest cell formation and migration in the developing embryo, FASEB J, vol.8, pp.699-706, 1994.

, Genomic Classification of Cutaneous Melanoma, Cancer Genome Atlas N, vol.161, pp.1681-1696, 2015.

J. Cao, L. Wan, E. Hacker, X. Dai, S. Lenna et al., MC1R is a potent regulator of PTEN after UV exposure in melanocytes, Mol Cell, vol.51, pp.409-422, 2013.

M. S. Carlino and G. V. Long, Ipilimumab Combined with Nivolumab: A Standard of Care for the Treatment of Advanced Melanoma?, Clin Cancer Res, vol.22, pp.3992-3998, 2016.

F. Carneiro, B. P. Kruithof, K. Balani, A. Agarwal, V. Gaussin et al., Relationships between melanocytes, mechanical properties and extracellular matrix composition in mouse heart valves, Journal of long-term effects of medical implants, vol.25, pp.17-26, 2015.

S. Carreira, J. Goodall, L. Denat, M. Rodriguez, P. Nuciforo et al., Mitf regulation of Dia1 controls melanoma proliferation and invasiveness, Genes Dev, vol.20, pp.3426-3439, 2006.

R. D. Carvajal, C. R. Antonescu, J. D. Wolchok, P. B. Chapman, R. A. Roman et al., KIT as a therapeutic target in metastatic melanoma, JAMA, vol.305, pp.2327-2334, 2011.

R. D. Carvajal, J. A. Sosman, J. F. Quevedo, M. M. Milhem, A. M. Joshua et al., Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial, Jama, vol.311, pp.2397-2405, 2014.

E. Cerami, J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer et al., The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer discovery, vol.2, pp.401-404, 2012.

C. Chattopadhyay, D. W. Kim, D. S. Gombos, J. Oba, Y. Qin et al., Uveal melanoma: From diagnosis to treatment and the science in between, Cancer, vol.122, pp.2299-2312, 2016.

Y. Cheli, S. Giuliano, T. Botton, S. Rocchi, V. Hofman et al., Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny, Oncogene, vol.30, pp.2307-2318, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02530763

Y. Cheli, M. Ohanna, R. Ballotti, and C. Bertolotto, Fifteen-year quest for microphthalmia-associated transcription factor target genes, Pigment Cell Melanoma Res, vol.23, pp.27-40, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-02530740

K. C. Cheng, D. S. Cahill, H. Kasai, S. Nishimura, and L. A. Loeb, 8-Hydroxyguanine, an abundant form of oxidative DNA damage, causes G----T and A----C substitutions, J Biol Chem, vol.267, pp.166-172, 1992.

W. H. Clark, D. E. Elder, V. Horn, and M. , The biologic forms of malignant melanoma, Hum Pathol, vol.17, pp.443-450, 1986.

A. Conde-perez, G. Gros, C. Longvert, M. Pedersen, V. Petit et al., A caveolin-dependent and PI3K/AKTindependent role of PTEN in beta-catenin transcriptional activity, Nature communications, vol.6, p.8093, 2015.

J. A. Curtin, K. Busam, D. Pinkel, and B. C. Bastian, Somatic activation of KIT in distinct subtypes of melanoma, J Clin Oncol, vol.24, pp.4340-4346, 2006.

B. Damato, J. A. Dopierala, and S. E. Coupland, Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification, Clin Cancer Res, vol.16, pp.6083-6092, 2010.

W. E. Damsky, D. P. Curley, M. Santhanakrishnan, L. E. Rosenbaum, J. T. Platt et al., beta-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas, Cancer Cell, vol.20, pp.741-754, 2011.

R. Danielli, R. Ridolfi, V. Chiarion-sileni, P. Queirolo, A. Testori et al., Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy, Cancer immunology, immunotherapy : CII, vol.61, pp.41-48, 2012.

D. Dankort, D. P. Curley, R. A. Cartlidge, B. Nelson, A. N. Karnezis et al., Braf(V600E) cooperates with Pten loss to induce metastatic melanoma, Nat Genet, vol.41, pp.544-552, 2009.

H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins et al., Mutations of the BRAF gene in human cancer, Nature, vol.417, pp.949-954, 2002.

M. A. Davies, K. Stemke-hale, C. Tellez, T. L. Calderone, W. Deng et al., A novel AKT3 mutation in melanoma tumours and cell lines, Br J Cancer, vol.99, pp.1265-1268, 2008.

M. J. De-lange, L. Razzaq, M. Versluis, S. Verlinde, M. Dogrusoz et al., Distribution of GNAQ and GNA11 Mutation Signatures in Uveal Melanoma Points to a Light Dependent Mutation Mechanism, PloS one, vol.10, p.138002, 2015.

C. L. Decatur, E. Ong, N. Garg, H. Anbunathan, A. M. Bowcock et al., Driver Mutations in Uveal Melanoma: Associations With Gene Expression Profile and Patient Outcomes, JAMA ophthalmology, vol.134, pp.728-733, 2016.

V. Delmas, F. Beermann, S. Martinozzi, S. Carreira, J. Ackermann et al., Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development, Genes Dev, vol.21, pp.2923-2935, 2007.

C. Denoyelle, G. Abou-rjaily, V. Bezrookove, M. Verhaegen, T. M. Johnson et al., Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway, Nat Cell Biol, vol.8, pp.1053-1063, 2006.

A. S. Dhillon, S. Hagan, O. Rath, and W. Kolch, MAP kinase signalling pathways in cancer, Oncogene, vol.26, pp.3279-3290, 2007.

N. Dhomen, J. S. Reis-filho, S. Da-rocha-dias, R. Hayward, K. Savage et al., Oncogenic Braf induces melanocyte senescence and melanoma in mice, Cancer Cell, vol.15, pp.294-303, 2009.

M. Diener-west, S. M. Reynolds, D. J. Agugliaro, R. Caldwell, K. Cumming et al., Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma, Archives of ophthalmology, vol.123, pp.1639-1643, 2005.

S. Dithmar, C. E. Diaz, and H. E. Grossniklaus, Intraocular melanoma spread to regional lymph nodes: report of two cases, Retina, vol.20, pp.76-79, 2000.

F. Dupuy, S. Tabaries, S. Andrzejewski, Z. Dong, J. Blagih et al., PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer, Cell metabolism, vol.22, pp.577-589, 2015.

J. P. Ehlers, L. Worley, M. D. Onken, and J. W. Harbour, Integrative genomic analysis of aneuploidy in uveal melanoma, Clin Cancer Res, vol.14, pp.115-122, 2008.

C. M. Emery, K. G. Vijayendran, M. C. Zipser, A. M. Sawyer, L. Niu et al., MEK1 mutations confer resistance to MEK and B-RAF inhibition, Proc Natl Acad Sci U S A, vol.106, pp.20411-20416, 2009.

M. Ennen, C. Keime, D. Kobi, G. Mengus, D. Lipsker et al., Single-cell gene expression signatures reveal melanoma cell heterogeneity, Oncogene, vol.34, pp.3251-3263, 2015.

P. Falletta, L. Sanchez-del-campo, J. Chauhan, M. Effern, A. Kenyon et al., Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma, Genes Dev, 2017.

X. Feng, M. S. Degese, R. Iglesias-bartolome, J. P. Vaque, A. A. Molinolo et al., Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trioregulated rho GTPase signaling circuitry, Cancer Cell, vol.25, pp.831-845, 2014.

R. Ferguson, M. Vogelsang, E. Ucisik-akkaya, K. Rai, R. Pilarski et al., Genetic markers of pigmentation are novel risk loci for uveal melanoma, Scientific reports, vol.6, p.31191, 2016.

M. G. Field, C. L. Decatur, S. Kurtenbach, G. Gezgin, P. A. Van-der-velden et al., PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma, Clin Cancer Res, vol.22, pp.1234-1242, 2016.

M. G. Field, M. A. Durante, C. L. Decatur, B. Tarlan, K. M. Oelschlager et al., Epigenetic reprogramming and aberrant expression of PRAME are associated with increased metastatic risk in Class 1 and Class 2 uveal melanomas, Oncotarget, 2016.

M. G. Field and J. W. Harbour, Recent developments in prognostic and predictive testing in uveal melanoma, Current opinion in ophthalmology, vol.25, pp.234-239, 2014.

B. Fine, C. Hodakoski, S. Koujak, T. Su, L. H. Saal et al., Activation of the PI3K pathway in cancer through inhibition of PTEN by exchange factor P-REX2a, Science, vol.325, pp.1261-1265, 2009.

O. Fletcher, D. Easton, K. Anderson, C. Gilham, J. M. Peto et al., Lifetime risks of common cancers among retinoblastoma survivors, J Natl Cancer Inst, vol.96, pp.357-363, 2004.

J. H. Francis, T. Wiesner, T. Milman, H. H. Won, A. Lin et al., Investigation of Somatic GNAQ, GNA11, BAP1 and SF3B1 Mutations in Ophthalmic Melanocytomas, Ocular oncology and pathology, vol.2, pp.171-177, 2016.

C. Furman, S. M. Short, R. R. Subramanian, B. R. Zetter, and T. M. Roberts, DEF-1/ASAP1 is a GTPase-activating protein (GAP) for ARF1 that enhances cell motility through a GAP-dependent mechanism, J Biol Chem, vol.277, pp.7962-7969, 2002.

S. J. Furney, M. Pedersen, D. Gentien, A. G. Dumont, A. Rapinat et al., SF3B1 mutations are associated with alternative splicing in uveal melanoma, Cancer discovery, vol.3, pp.1122-1129, 2013.

J. Gao, B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Science signaling, vol.6, p.1, 2013.

M. J. Garnett and R. Marais, Guilty as charged: B-RAF is a human oncogene, Cancer Cell, vol.6, pp.313-319, 2004.

L. A. Garraway, H. R. Widlund, M. A. Rubin, G. Getz, A. J. Berger et al., Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma, Nature, vol.436, pp.117-122, 2005.

P. Ghiorzo, L. Pastorino, P. Queirolo, W. Bruno, M. G. Tibiletti et al., Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history, Pigment Cell Melanoma Res, vol.26, pp.259-262, 2013.

S. Giuliano, Y. Cheli, M. Ohanna, C. Bonet, L. Beuret et al., Microphthalmia-associated transcription factor controls the DNA damage response and a lineage-specific senescence program in melanomas, Cancer Res, vol.70, pp.3813-3822, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-02530789

K. G. Griewank and R. Murali, Pathology and genetics of uveal melanoma, Pathology, vol.45, pp.18-27, 2013.

K. G. Griewank, H. Westekemper, R. Murali, M. Mach, B. Schilling et al., Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas, Clin Cancer Res, vol.19, pp.3143-3152, 2013.

M. P. Gupta, A. M. Lane, M. M. Deangelis, K. Mayne, M. Crabtree et al., Clinical Characteristics of Uveal Melanoma in Patients With Germline BAP1 Mutations, JAMA ophthalmology, vol.133, pp.881-887, 2015.

R. Gutzmer, L. Rivoltini, E. Levchenko, A. Testori, J. Utikal et al., Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study, p.68, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01406639

J. W. Harbour, M. D. Onken, E. D. Roberson, S. Duan, L. Cao et al., Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, vol.330, pp.1410-1413, 2010.

J. W. Harbour, E. D. Roberson, H. Anbunathan, M. D. Onken, L. A. Worley et al., Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma, Nat Genet, vol.45, pp.133-135, 2013.

R. S. Harris, Cancer mutation signatures, DNA damage mechanisms, and potential clinical implications, Genome medicine, vol.5, p.87, 2013.

N. Hearle, B. E. Damato, J. Humphreys, J. Wixey, H. Green et al., Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma, Invest Ophthalmol Vis Sci, vol.44, pp.458-462, 2003.

N. Hearle, J. Humphreys, B. E. Damato, R. Wort, R. Talaban et al., Role of MC1R variants in uveal melanoma, Br J Cancer, vol.89, pp.1961-1965, 2003.

C. Herraiz, J. C. Garcia-borron, C. Jimenez-cervantes, and C. Olivares, MC1R signaling. Intracellular partners and pathophysiological implications, Biochim Biophys Acta, 2017.

F. S. Hodi, S. J. O'day, D. F. Mcdermott, R. W. Weber, J. A. Sosman et al., Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, vol.363, pp.711-723, 2010.

E. Hodis, I. R. Watson, G. V. Kryukov, S. T. Arold, M. Imielinski et al., A landscape of driver mutations in melanoma, Cell, vol.150, pp.251-263, 2012.

K. S. Hoek, O. M. Eichhoff, N. C. Schlegel, U. Dobbeling, N. Kobert et al., In vivo switching of human melanoma cells between proliferative and invasive states, Cancer Res, vol.68, pp.650-656, 2008.

K. S. Hoek and C. R. Goding, Cancer stem cells versus phenotype-switching in melanoma, Pigment Cell Melanoma Res, vol.23, pp.746-759, 2010.

S. Horn, A. Figl, P. S. Rachakonda, C. Fischer, A. Sucker et al., TERT promoter mutations in familial and sporadic melanoma, Science, vol.339, pp.959-961, 2013.

S. K. Horrigan, P. Courville, D. Sampey, F. Zhou, S. Cai et al., Replication Study: Melanoma genome sequencing reveals frequent PREX2 mutations, vol.6, 2017.

A. Hoshino, B. Costa-silva, T. L. Shen, G. Rodrigues, A. Hashimoto et al., Tumour exosome integrins determine organotropic metastasis, Nature, vol.527, pp.329-335, 2015.

C. J. Hussussian, J. P. Struewing, A. M. Goldstein, P. A. Higgins, D. S. Ally et al., Germline p16 mutations in familial melanoma, Nat Genet, vol.8, pp.15-21, 1994.

I. H. Ismail, R. Davidson, J. P. Gagne, Z. Z. Xu, G. G. Poirier et al., Germline mutations in BAP1 impair its function in DNA double-strand break repair, Cancer Res, vol.74, pp.4282-4294, 2014.

F. Janku, J. J. Lee, A. M. Tsimberidou, D. S. Hong, A. Naing et al., PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers, PloS one, vol.6, p.22769, 2011.

C. M. Johannessen, L. A. Johnson, F. Piccioni, A. Townes, D. T. Frederick et al., A melanocyte lineage program confers resistance to MAP kinase pathway inhibition, Nature, vol.504, pp.138-142, 2013.

P. Johansson, L. G. Aoude, K. Wadt, W. J. Glasson, S. K. Warrier et al., Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4, Oncotarget, vol.7, pp.4624-4631, 2016.

P. Jovanovic, M. Mihajlovic, J. Djordjevic-jocic, S. Vlajkovic, S. Cekic et al., Ocular melanoma: an overview of the current status, International journal of clinical and experimental pathology, vol.6, pp.1230-1244, 2013.

H. L. Kaufman, J. M. Kirkwood, F. S. Hodi, S. Agarwala, T. Amatruda et al., The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma, Nature reviews Clinical oncology, vol.10, pp.588-598, 2013.

K. Kemper, O. Krijgsman, P. Cornelissen-steijger, A. Shahrabi, F. Weeber et al., Intra-and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts, EMBO molecular medicine, vol.7, pp.1104-1118, 2015.

N. Kenawy, S. L. Lake, S. E. Coupland, and B. E. Damato, Conjunctival melanoma and melanocytic intra-epithelial neoplasia, Eye (Lond), vol.27, pp.142-152, 2013.

D. J. Konieczkowski, C. M. Johannessen, O. Abudayyeh, J. W. Kim, Z. A. Cooper et al., A Melanoma Cell State Distinction Influences Sensitivity to MAPK Pathway Inhibitors, Cancer discovery, 2014.

L. A. Kottschade, R. R. Mcwilliams, S. N. Markovic, M. S. Block, V. Bisneto et al., The use of pembrolizumab for the treatment of metastatic uveal melanoma, Melanoma Res, vol.26, pp.300-303, 2016.

M. Krauthammer, Y. Kong, A. Bacchiocchi, P. Evans, N. Pornputtapong et al., Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas, Nat Genet, vol.47, pp.996-1002, 2015.

M. Krauthammer, Y. Kong, B. H. Ha, P. Evans, A. Bacchiocchi et al., Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma, Nat Genet, vol.44, pp.1006-1014, 2012.

G. Krygier, K. Lombardo, C. Vargas, I. Alvez, R. Costa et al., Familial uveal melanoma: report on three sibling cases, The British journal of ophthalmology, vol.85, pp.1007-1008, 2001.

E. Kujala and T. Kivela, Tumor, node, metastasis classification of malignant ciliary body and choroidal melanoma evaluation of the 6th edition and future directions, Ophthalmology, vol.112, pp.1135-1144, 2005.

S. Landreville, O. A. Agapova, K. A. Matatall, Z. T. Kneass, M. D. Onken et al., Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma, Clin Cancer Res, vol.18, pp.408-416, 2012.

J. Landsberg, J. Kohlmeyer, M. Renn, T. Bald, M. Rogava et al., Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation, Nature, vol.490, pp.412-416, 2012.

L. Larue and V. Delmas, The WNT/Beta-catenin pathway in melanoma, Frontiers in bioscience : a journal and virtual library, vol.11, pp.733-742, 2006.

M. S. Lawrence, P. Stojanov, P. Polak, G. V. Kryukov, K. Cibulskis et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, vol.499, pp.214-218, 2013.

M. D. Levin, M. M. Lu, N. B. Petrenko, B. J. Hawkins, T. H. Gupta et al., Melanocyte-like cells in the heart and pulmonary veins contribute to atrial arrhythmia triggers, J Clin Invest, vol.119, pp.3420-3436, 2009.

G. V. Long, D. Stroyakovskiy, H. Gogas, E. Levchenko, F. De-braud et al., Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, vol.371, pp.1877-1888, 2014.

A. M. Lyon and J. J. Tesmer, Structural insights into phospholipase C-beta function, Molecular pharmacology, vol.84, pp.488-500, 2013.

K. M. Mahoney, G. J. Freeman, and D. F. Mcdermott, The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma, Clinical therapeutics, vol.37, pp.764-782, 2015.

M. Martin, L. Masshofer, P. Temming, S. Rahmann, C. Metz et al., Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3, Nat Genet, vol.45, pp.933-936, 2013.

R. Massoumi, C. K. Nielsen, D. Azemovic, and A. Sjolander, Leukotriene D4-induced adhesion of Caco-2 cells is mediated by prostaglandin E2 and upregulation of alpha2beta1-integrin, Exp Cell Res, vol.289, pp.342-351, 2003.

K. A. Matatall, O. A. Agapova, M. D. Onken, L. A. Worley, A. M. Bowcock et al., BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma, BMC cancer, vol.13, p.371, 2013.

R. Mayor and E. Theveneau, The neural crest, Development, vol.140, pp.2247-2251, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01712198

K. C. Mckenna and P. W. Chen, Influence of immune privilege on ocular tumor development, Ocular immunology and inflammation, vol.18, pp.80-90, 2010.

C. C. Mclaughlin, X. C. Wu, A. Jemal, H. J. Martin, L. M. Roche et al., Incidence of noncutaneous melanomas in the U, S. Cancer, vol.103, pp.1000-1007, 2005.

J. A. Metzelaar-blok, J. A. Ter-huurne, H. M. Hurks, J. E. Keunen, M. J. Jager et al., Characterization of melanocortin-1 receptor gene variants in uveal melanoma patients, Invest Ophthalmol Vis Sci, vol.42, pp.1951-1954, 2001.

N. Meyer and L. Z. Penn, Reflecting on 25 years with MYC, Nat Rev Cancer, vol.8, pp.976-990, 2008.

M. Mezhybovska, K. Wikstrom, J. F. Ohd, and A. Sjolander, Pro-inflammatory mediator leukotriene D4 induces transcriptional activity of potentially oncogenic genes, Biochemical Society transactions, vol.33, pp.698-700, 2005.

C. Michaloglou, L. C. Vredeveld, M. S. Soengas, C. Denoyelle, T. Kuilman et al., BRAFE600-associated senescence-like cell cycle arrest of human naevi, Nature, vol.436, pp.720-724, 2005.

A. Mirmohammadsadegh, A. Marini, S. Nambiar, M. Hassan, A. Tannapfel et al., Epigenetic silencing of the PTEN gene in melanoma, Cancer Res, vol.66, pp.6546-6552, 2006.

G. S. Missotten, S. Keijser, D. Keizer, R. J. , D. Wolff-rouendaal et al., Conjunctival melanoma in the Netherlands: a nationwide study, Invest Ophthalmol Vis Sci, vol.46, pp.75-82, 2005.

D. Mitra, X. Luo, A. Morgan, J. Wang, M. P. Hoang et al., An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background, Nature, vol.491, pp.449-453, 2012.

S. Mong, J. Miller, H. L. Wu, and S. T. Crooke, Leukotriene D4 receptor-mediated hydrolysis of phosphoinositide and mobilization of calcium in sheep tracheal smooth muscle cells, The Journal of pharmacology and experimental therapeutics, vol.244, pp.508-515, 1988.

A. R. Moore, E. Ceraudo, J. J. Sher, Y. Guan, A. N. Shoushtari et al., Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma, Nat Genet, vol.48, pp.675-680, 2016.

J. G. Morelli, J. J. Yohn, M. B. Lyons, R. C. Murphy, and D. A. Norris, Leukotrienes C4 and D4 as potent mitogens for cultured human neonatal melanocytes, J Invest Dermatol, vol.93, pp.719-722, 1989.

J. Muller, O. Krijgsman, J. Tsoi, L. Robert, W. Hugo et al., Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma, Nature communications, vol.5, p.5712, 2014.

T. Muller, U. Stein, A. Poletti, L. Garzia, M. Rothley et al., ASAP1 promotes tumor cell motility and invasiveness, stimulates metastasis formation in vivo, and correlates with poor survival in colorectal cancer patients, Oncogene, vol.29, pp.2393-2403, 2010.

R. Murali, T. Wiesner, M. K. Rosenblum, and B. C. Bastian, GNAQ and GNA11 mutations in melanocytomas of the central nervous system, Acta neuropathologica, vol.123, pp.457-459, 2012.

F. Nallet-staub, V. Marsaud, L. Li, C. Gilbert, S. Dodier et al., Pro-invasive activity of the Hippo pathway effectors YAP and TAZ in cutaneous melanoma, J Invest Dermatol, vol.134, pp.123-132, 2014.

T. Network, Genomic Classification of Cutaneous Melanoma, Cell, vol.161, pp.1681-1696, 2015.

S. I. Nikolaev, D. Rimoldi, C. Iseli, A. Valsesia, D. Robyr et al., Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma, Nat Genet, vol.44, pp.133-139, 2011.

M. Ohanna, S. Giuliano, C. Bonet, V. Imbert, V. Hofman et al., Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS), Genes Dev, vol.25, pp.1245-1261, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02530715

M. Oliva, A. J. Rullan, and J. M. Piulats, Uveal melanoma as a target for immunetherapy, Annals of translational medicine, vol.4, p.172, 2016.

M. D. Onken, J. P. Ehlers, L. A. Worley, J. Makita, Y. Yokota et al., Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas, Cancer Res, vol.66, pp.4602-4609, 2006.

M. D. Onken, L. A. Worley, J. P. Ehlers, and J. W. Harbour, Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death, Cancer Res, vol.64, pp.7205-7209, 2004.

M. D. Onken, L. A. Worley, and J. W. Harbour, Association between gene expression profile, proliferation and metastasis in uveal melanoma, Current eye research, vol.35, pp.857-863, 2010.

M. D. Onken, L. A. Worley, M. D. Long, S. Duan, M. L. Council et al., Oncogenic mutations in GNAQ occur early in uveal melanoma, Invest Ophthalmol Vis Sci, vol.49, pp.5230-5234, 2008.

M. D. Onken, L. A. Worley, M. D. Tuscan, and J. W. Harbour, An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma, The Journal of molecular diagnostics : JMD, vol.12, pp.461-468, 2010.

P. L. Patel, A. Suram, N. Mirani, O. Bischof, and U. Herbig, Derepression of hTERT gene expression promotes escape from oncogene-induced cellular senescence, Proc Natl Acad Sci U S A, vol.113, pp.5024-5033, 2016.

C. Pirker, K. Holzmann, S. Spiegl-kreinecker, L. Elbling, C. Thallinger et al., Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes, Melanoma Res, vol.13, pp.483-492, 2003.

A. Platz, S. Egyhazi, U. Ringborg, and J. Hansson, Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site, Molecular oncology, vol.1, pp.395-405, 2008.

P. M. Pollock, U. L. Harper, K. S. Hansen, L. M. Yudt, M. Stark et al., High frequency of BRAF mutations in nevi, Nat Genet, vol.33, pp.19-20, 2003.

J. L. Rees, The genetics of sun sensitivity in humans, Am J Hum Genet, vol.75, pp.739-751, 2004.

S. Riesenberg, A. Groetchen, R. Siddaway, T. Bald, J. Reinhardt et al., MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment, Nature communications, vol.6, p.8755, 2015.

P. Rietschel, K. S. Panageas, C. Hanlon, A. Patel, D. H. Abramson et al., Variates of survival in metastatic uveal melanoma, J Clin Oncol, vol.23, pp.8076-8080, 2005.

B. Royer-bertrand, M. Torsello, D. Rimoldi, E. Zaoui, I. Cisarova et al., Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing, Am J Hum Genet, 2016.

T. Sarna, Properties and function of the ocular melanin--a photobiophysical view, Journal of photochemistry and photobiology B, Biology, vol.12, pp.215-258, 1992.

G. Scelo, V. Constantinescu, I. Csiki, D. Zaridze, N. Szeszenia-dabrowska et al., Occupational exposure to vinyl chloride, acrylonitrile and styrene and lung cancer risk (europe), Cancer Causes Control, vol.15, pp.445-452, 2004.

H. B. Schioth, S. R. Phillips, R. Rudzish, M. A. Birch-machin, J. E. Wikberg et al., Loss of function mutations of the human melanocortin 1 receptor are common and are associated with red hair, Biochem Biophys Res Commun, vol.260, pp.488-491, 1999.

S. Schmidt and A. Debant, Aptamer-derived peptide inhibitors of Rho guanine nucleotide exchange factors. The Enzymes 33 Pt A, pp.147-168, 2013.

R. Schrage, A. L. Schmitz, E. Gaffal, S. Annala, S. Kehraus et al., The experimental power of FR900359 to study Gq-regulated biological processes, Nature communications, vol.6, p.10156, 2015.

J. M. Seddon, E. S. Gragoudas, R. J. Glynn, K. M. Egan, D. M. Albert et al., Host factors, UV radiation, and risk of uveal melanoma. A case-control study, Archives of ophthalmology, vol.108, pp.1274-1280, 1990.

M. Sharpe and N. Mount, Genetically modified T cells in cancer therapy: opportunities and challenges, Disease models & mechanisms, vol.8, pp.337-350, 2015.

C. J. Sherr and F. Mccormick, The RB and p53 pathways in cancer, Cancer Cell, vol.2, pp.103-112, 2002.

C. L. Shields, A. Ganguly, C. G. Bianciotto, K. Turaka, A. Tavallali et al., Prognosis of uveal melanoma in 500 cases using genetic testing of fineneedle aspiration biopsy specimens, Ophthalmology, vol.118, pp.396-401, 2011.

C. L. Shields, J. S. Markowitz, I. Belinsky, H. Schwartzstein, N. S. George et al., Conjunctival melanoma: outcomes based on tumor origin in 382 consecutive cases, Ophthalmology, vol.118, pp.389-395, 2011.

E. Shtivelman, M. Q. Davies, P. Hwu, J. Yang, M. Lotem et al., Pathways and therapeutic targets in melanoma, Oncotarget, vol.5, pp.1701-1752, 2014.

A. Y. Shull, A. Latham-schwark, P. Ramasamy, K. Leskoske, D. Oroian et al., Novel somatic mutations to PI3K pathway genes in metastatic melanoma, PloS one, vol.7, p.43369, 2012.

A. D. Singh, L. Bergman, and S. Seregard, Uveal melanoma: epidemiologic aspects, Ophthalmology clinics of North America, vol.18, pp.75-84, 2005.

A. D. Singh and A. Topham, Incidence of uveal melanoma in the United States: 1973-1997, Ophthalmology, vol.110, pp.956-961, 2003.

E. Steingrimsson, N. G. Copeland, and N. A. Jenkins, Melanocytes and the microphthalmia transcription factor network, Annu Rev Genet, vol.38, pp.365-411, 2004.

T. Strub, S. Giuliano, T. Ye, C. Bonet, C. Keime et al., Essential role of microphthalmia transcription factor for DNA replication, mitosis and genomic stability in melanoma, Oncogene, vol.30, pp.2319-2332, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02530755

R. A. Sturm and M. Larsson, Genetics of human iris colour and patterns, Pigment Cell Melanoma Res, vol.22, pp.544-562, 2009.

R. J. Sullivan and K. T. Flaherty, Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma, Nature reviews Clinical oncology, vol.12, pp.2424-2435, 2015.

A. Sveen, S. Kilpinen, A. Ruusulehto, R. A. Lothe, and R. I. Skotheim, Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes, Oncogene, vol.35, pp.2413-2427, 2016.

M. Tachibana, Sound needs sound melanocytes to be heard, Pigment Cell Res, vol.12, pp.344-354, 1999.

K. Takeda, N. H. Takahashi, and S. Shibahara, Neuroendocrine functions of melanocytes: beyond the skin-deep melanin maker, The Tohoku journal of experimental medicine, vol.211, pp.201-221, 2007.

F. Tas, Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors, Journal of oncology, p.647684, 2012.

C. Tatsi, F. Bacopoulou, C. Lyssikatos, E. Belyavskaya, F. R. Faucz et al., Sporadic melanotic schwannoma with overlapping features of melanocytoma bearing a GNA11 mutation in an adolescent girl, Pediatric blood & cancer, 2016.

N. E. Thomas, BRAF somatic mutations in malignant melanoma and melanocytic naevi, Melanoma Res, vol.16, pp.97-103, 2006.

I. Tirosh, B. Izar, S. M. Prakadan, M. H. Wadsworth, D. Treacy et al., Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq, Science, vol.352, pp.189-196, 2016.

S. L. Topalian, M. Sznol, D. F. Mcdermott, H. M. Kluger, R. D. Carvajal et al., Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab, J Clin Oncol, vol.32, pp.1020-1030, 2014.

E. Triay, L. Bergman, B. Nilsson, C. All-ericsson, and S. Seregard, Time trends in the incidence of conjunctival melanoma in Sweden, The British journal of ophthalmology, vol.93, pp.1524-1528, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00477850

J. Trolet, P. Hupe, I. Huon, I. Lebigot, C. Decraene et al., Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases, Invest Ophthalmol Vis Sci, vol.50, pp.2572-2580, 2009.

K. K. Tsai, I. Zarzoso, and A. I. Daud, PD-1 and PD-L1 antibodies for melanoma, Human vaccines & immunotherapeutics, vol.10, pp.3111-3116, 2014.

T. Tsai, C. Vu, and D. E. Henson, Cutaneous, ocular and visceral melanoma in African Americans and Caucasians, Melanoma Res, vol.15, pp.213-217, 2005.

H. Tsao, C. Bevona, W. Goggins, and T. Quinn, The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate, Arch Dermatol, vol.139, pp.282-288, 2003.

H. Tsao, V. Goel, H. Wu, G. Yang, and F. G. Haluska, Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma, J Invest Dermatol, vol.122, pp.337-341, 2004.

S. Ugurel, J. Rohmel, P. A. Ascierto, K. T. Flaherty, J. J. Grob et al., Survival of patients with advanced metastatic melanoma: The impact of novel therapies, Eur J Cancer, vol.53, pp.125-134, 2016.

C. Vajdic, A. Kricker, D. L. Duffy, J. F. Aitken, M. Stark et al., Ocular melanoma is not associated with CDKN2A or MC1R variants--a population-based study, Melanoma Res, vol.13, pp.409-413, 2003.

C. M. Vajdic, A. Kricker, M. Giblin, J. Mckenzie, J. Aitken et al., Sun exposure predicts risk of ocular melanoma in Australia, Int J Cancer, vol.101, pp.175-182, 2002.

E. M. Van-allen, N. Wagle, A. Sucker, D. J. Treacy, C. M. Johannessen et al., Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis, Invest Ophthalmol Vis Sci, vol.53, pp.2668-2674, 2010.

M. K. Van-der-kooij, A. Joosse, F. M. Speetjens, G. A. Hospers, C. Bisschop et al., Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma, Acta oncologica, vol.56, pp.5303-5306, 2001.

C. D. Van-raamsdonk, V. Bezrookove, G. Green, J. Bauer, L. Gaugler et al., Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi, Nature, vol.457, pp.599-602, 2009.

C. D. Van-raamsdonk, K. G. Griewank, M. B. Crosby, M. C. Garrido, S. Vemula et al., Mutations in GNA11 in uveal melanoma, N Engl J Med, vol.363, pp.2191-2199, 2010.

A. Verfaillie, H. Imrichova, Z. K. Atak, M. Dewaele, F. Rambow et al., Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state, Nature communications, vol.6, p.6683, 2015.

M. Versluis, M. J. De-lange, S. I. Van-pelt, C. A. Ruivenkamp, W. G. Kroes et al., Digital PCR validates 8q dosage as prognostic tool in uveal melanoma, PloS one, vol.10, p.116371, 2015.

J. Villanueva, J. R. Infante, C. Krepler, P. Reyes-uribe, M. Samanta et al., Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma, Cell reports, vol.4, pp.1090-1099, 2013.

B. Vogelstein, N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz et al., Cancer genome landscapes, Science, vol.339, pp.1546-1558, 2013.

L. C. Vredeveld, P. A. Possik, M. A. Smit, K. Meissl, C. Michaloglou et al., Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis, Genes Dev, vol.26, pp.1055-1069, 2012.

K. Wakamatsu, D. N. Hu, S. A. Mccormick, and S. Ito, Characterization of melanin in human iridal and choroidal melanocytes from eyes with various colored irides, Pigment Cell Melanoma Res, vol.21, pp.97-105, 2008.

X. Wei, V. Walia, J. C. Lin, J. K. Teer, T. D. Prickett et al., Exome sequencing identifies GRIN2A as frequently mutated in melanoma, Nat Genet, vol.43, pp.442-446, 2011.

L. V. Weyden, M. J. Arends, A. D. Campbell, T. Bald, H. Wardle-jones et al., Genome-wide in vivo screen identifies novel host regulators of metastatic colonization, Nature, vol.541, pp.233-236, 2017.

T. Wiesner, A. C. Obenauf, R. Murali, I. Fried, K. G. Griewank et al., Germline mutations in BAP1 predispose to melanocytic tumors, Nat Genet, vol.43, pp.1018-1021, 2011.

K. Wikstrom, M. Juhas, and A. Sjolander, The anti-apoptotic effect of leukotriene D4 involves the prevention of caspase 8 activation and Bid cleavage, Biochem J, vol.371, pp.115-124, 2003.

K. Wikstrom, J. F. Ohd, and A. Sjolander, Regulation of leukotriene-dependent induction of cyclooxygenase-2 and Bcl-2, Biochem Biophys Res Commun, vol.302, pp.330-335, 2003.

Y. M. Wilson, K. L. Richards, M. L. Ford-perriss, J. J. Panthier, and M. Murphy, Neural crest cell lineage segregation in the mouse neural tube, Development, vol.131, pp.6153-6162, 2004.

E. Wisse, F. Jacobs, B. Topal, P. Frederik, D. Geest et al., The size of endothelial fenestrae in human liver sinusoids: implications for hepatocyte-directed gene transfer, Gene therapy, vol.15, pp.1193-1199, 2008.

J. R. Wong, A. A. Nanji, A. Galor, and C. L. Karp, Management of conjunctival malignant melanoma: a review and update, Expert review of ophthalmology, vol.9, pp.185-204, 2014.

H. Wu, V. Goel, and F. G. Haluska, PTEN signaling pathways in melanoma, Oncogene, vol.22, pp.3113-3122, 2003.

F. Wunder, H. Tinel, R. Kast, A. Geerts, E. M. Becker et al., Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor, British journal of pharmacology, vol.160, pp.399-409, 2010.

S. Yavuzyigitoglu, A. E. Koopmans, R. M. Verdijk, J. Vaarwater, B. Eussen et al., Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases, Ophthalmology, vol.123, pp.1118-1128, 2016.

S. Yokoyama, S. L. Woods, G. M. Boyle, L. G. Aoude, S. Macgregor et al., A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma, Nature, vol.480, pp.99-103, 2011.

J. H. Yoo, D. S. Shi, A. H. Grossmann, L. K. Sorensen, Z. Tong et al., ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma, Cancer Cell, vol.29, pp.889-904, 2016.

F. X. Yu, J. Luo, J. S. Mo, G. Liu, Y. C. Kim et al., Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP, Cancer Cell, vol.25, pp.822-830, 2014.

B. Zbytek, J. A. Carlson, J. Granese, J. Ross, M. C. Mihm et al., Current concepts of metastasis in melanoma, Expert review of dermatology, vol.3, pp.569-585, 2008.

L. Zecca, L. Casella, A. Albertini, C. Bellei, F. A. Zucca et al., Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease, J Neurochem, vol.106, pp.1866-1875, 2008.

J. Zhang and J. L. Manley, Misregulation of pre-mRNA alternative splicing in cancer, Cancer discovery, vol.3, pp.1228-1237, 2013.

T. Zhang, K. Dutton-regester, K. M. Brown, and N. K. Hayward, The genomic landscape of cutaneous melanoma, Pigment Cell Melanoma Res, vol.29, pp.266-283, 2016.

D. Zhuang, S. Mannava, V. Grachtchouk, W. H. Tang, S. Patil et al., C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells, Oncogene, vol.27, pp.6623-6634, 2008.

L. Zuo, J. Weger, Q. Yang, A. M. Goldstein, M. A. Tucker et al., Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma, Nat Genet, vol.12, pp.97-99, 1996.